Back to results

CompletedPhase 3

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications

NCT00097786

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Multiple Locations, New Jersey, United States

+37 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2002-01
Enrollment: 9,306 participants
Sponsor: Novartis Pharmaceuticals
Purpose: prevention

Locations (38)

Multiple Locations, New Jersey, United States
Investigative Site, Argentina
Investigative Site, Australia
Multiple Locations, Austria
Investigative Site, Belgium
Investigative Site, Brazil
Investigative Site, Canada
Investigative Site, Chile
Investigative Site, China
Investigative Site, Colombia
Investigative Site, Czechia
Investigative Site, Denmark
Investigative Site, Ecuador
Investigative Site, Finland
Investigative Site, France
Investigative Site, Germany
Investigative Site, Greece
Investigative Site, Guatemala
Investigative Site, Hong Kong
Investigative Site, Hungary
Investigative Site, Italy
Investigative Site, Malaysia
Investigative Site, Mexico
Investigative Site, Netherlands
Investigative Site, Norway
Investigative Site, Peru
Investigative Site, Poland
Investigative Site, Russia
Investigative Site, Singapore
Investigative Site, Slovakia
Investigative Site, South Africa
Investigative Site, Spain
Investigative Site, Sweden
Investigative Site, Switzerland
Investigative Site, Taiwan
Investigative Site, Turkey (Türkiye)
Investigative Site, United Kingdom
Investigative Site, Uruguay

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications — TrialFind